CureVac (NASDAQ:CVAC) Shares Gap Up - Here's What Happened

CureVac (NASDAQ:CVAC - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $4.07, but opened at $5.36. CureVac shares last traded at $5.39, with a volume of 9,523,255 shares.

Analyst Ratings Changes

CVAC has been the topic of several research reports. UBS Group dropped their price target on shares of CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. JMP Securities reiterated a "market outperform" rating and issued a $10.00 price target on shares of CureVac in a research report on Wednesday, May 28th.

CureVac Trading Up 37.6%

The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The firm's 50-day simple moving average is $3.70 and its 200 day simple moving average is $3.46. The stock has a market capitalization of $1.26 billion, a P/E ratio of 10.18 and a beta of 2.49.

CureVac (NASDAQ:CVAC - Get Free Report) last posted its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). The company had revenue of $0.94 million for the quarter, compared to analyst estimates of $4.27 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%. Equities research analysts anticipate that CureVac will post 0.72 EPS for the current fiscal year.

Institutional Trading of CureVac

Several institutional investors and hedge funds have recently bought and sold shares of CVAC. Signaturefd LLC raised its holdings in CureVac by 29.2% during the 4th quarter. Signaturefd LLC now owns 36,140 shares of the company's stock worth $123,000 after buying an additional 8,170 shares during the period. Geode Capital Management LLC raised its holdings in CureVac by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock worth $824,000 after buying an additional 22,491 shares during the period. Quadrant Capital Group LLC raised its holdings in CureVac by 61.8% during the 4th quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company's stock worth $171,000 after buying an additional 19,098 shares during the period. Barclays PLC raised its holdings in CureVac by 51.8% during the 4th quarter. Barclays PLC now owns 34,836 shares of the company's stock worth $118,000 after buying an additional 11,890 shares during the period. Finally, XTX Topco Ltd raised its holdings in CureVac by 90.2% during the 4th quarter. XTX Topco Ltd now owns 24,365 shares of the company's stock worth $83,000 after buying an additional 11,553 shares during the period. Institutional investors and hedge funds own 17.26% of the company's stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.